KM Research Hub
← 返回论文库
待处理 入排:排除 图源:待检查

AERIFY-1/2: two phase 3, randomised, controlled trials of itepekimab in former smokers with moderate-to-severe COPD.

Klaus F Rabe, Fernando J Martinez, Surya P Bhatt, Tomotaka Kawayama, Borja G Cosio, Robert M Mroz, Maarten M Boomsma, Helene Goulaouic, Michael C Nivens, Michel Djandji, Xavier Soler, Ying Liu, Matthew P Kosloski, Christine R Xu, Nikhil Amin, Heribert Staudinger, David J Lederer, Raolat M Abdulai

ERJ Open Res 10(5) 00718-2023

PMID39319046
PMCIDPMC11417606
DOI10.1183/23120541.00718-2023
发表日期2024-09-25
摘要

摘要

BACKGROUND: Accumulating data implicate interleukin (IL)-33, a proinflammatory cytokine released locally upon epithelial cell damage, in the pathogenesis of COPD. In a phase 2 study, itepekimab, a human monoclonal antibody against IL-33, reduced exacerbations and improved lung function in a subgroup analysis of former smokers with COPD with an acceptable safety profile. METHODS: The study designs of AERIFY-1 and AERIFY-2 are described in this article. DISCUSSION: The primary objective of AERIFY-1/2 (NCT04701983/NCT04751487), two phase 3 randomised, double-blind, placebo-controlled trials, is to assess the efficacy and safety of itepekimab versus placebo in a population of former smokers with moderate-to-severe COPD over up to 52 weeks. An additional secondary population of current smokers are being enrolled in AERIFY-2. These two studies will enrol patients (aged 40-85 years) with COPD and chronic bronchitis who had ≥2 moderate or ≥ 1 severe exacerbations within the previous year despite standard-of-care triple or double background therapy. All participants are required to have ≥10-pack-year smoking history, and ≥6 months since smoking cessation for former smokers. The primary end-point is the annualised rate of moderate or severe acute exacerbation of COPD. Secondary end-points include change from baseline in pre- and post-bronchodilator forced expiratory volume in 1 s, and annualised frequency of severe exacerbations. Symptomatic end-points include Evaluating Respiratory Symptoms in COPD and St. George's Respiratory Questionnaire, safety and anti-drug antibody responses.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。